Steven Yatomi-Clarke, CEO & MD of Prescient Therapeutics (ASX:PTX) provides an update on the company’s next-gen CAR-T asset enhanced cell therapy capabilities – maybe the most promising global frontier in the fight against cancer – as well as their other cancer therapy programs.

Recorded on 14 August 2020 at 11 am (AEST).

Join the next Prescient Therapeutics webcast

Speak to our Advisor team about this company